top of page
At SEITO Biologics, we develop innovative immunotherapies that preferentially activate regulatory T cells, while sparing effector immune cells.

Our Mission

Tackling autoimmunity with selective Treg cell engagers (TREX)

A well-functioning immune system is essential for our health. This is also evident in patients suffering from autoimmune diseases, which affect an estimated 4% of the world population. There exist more than 80 different types of autoimmune diseases, including type 1 diabetes mellitus, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus. These diseases are chronic and lack a cure.


Effector immune cells are important to fighting dangerous microbes and cancer. However, in autoimmune diseases effector immune cells can attack healthy tissues because they are insufficiently controlled by regulatory T (Treg) cells. SEITO Biologics’ TREX immunotherapy selectively activates Treg cells, thereby restoring their function in autoimmune disease and preventing damage to healthy organs.

bottom of page